Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.800
+0.004 (0.44%)
At close: Mar 9, 2026, 4:00 PM EDT
0.732
-0.068 (-8.50%)
After-hours: Mar 9, 2026, 6:48 PM EDT
Pasithea Therapeutics Employees
Pasithea Therapeutics had 4 employees as of December 31, 2024. The number of employees decreased by 4 or -50.00% compared to the previous year.
Employees
4
Change (1Y)
-4
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$3,373,619
Market Cap
18.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | -4 | -50.00% |
| Dec 31, 2023 | 8 | -7 | -46.67% |
| Dec 31, 2022 | 15 | 10 | 200.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| IN8bio | 17 |
| Reviva Pharmaceuticals Holdings | 14 |
| VYNE Therapeutics | 13 |
| Genenta Science | 13 |
| Serina Therapeutics | 13 |
| Allarity Therapeutics | 7 |
| Intensity Therapeutics | 7 |
KTTA News
- 10 days ago - Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
- 20 days ago - Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 7 weeks ago - Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - GlobeNewsWire